Article Text

PDF

Clinical and research medicine: Coronary heart disease
e0421 Diagnostic value of plasma sRAGE in coronary artery disease and coronary artery disease with acute myocardial infarction (AMI)
  1. Guo Caixia1,
  2. Zhu Xinyuan1,
  3. Zhang Like2,
  4. Song Ke1,
  5. Xu Xiaowei1,
  6. Du Fenghe1
  1. 1Department of Cardiology Medicine, Beijing Tiantan Hospital Affiliate of Capital University of Medical Sciences, Beijing, China
  2. 2Department of Pathophysiology, Capital University of Medical Sciences, Beijing, China

Abstract

Objective To elucidate whether plasma soluble receptor for advanced glycation end products (sRAGE) is the biochemical markers indicating coronary artery disease and coronary artery disease with acute myocardial infarction (AMI).

Method Plasma levels of sRAGE was determined by enzyme linked immunoabsorbent assay in patients who came from Cardiology Department of Tiantan Hospital form March to May 2009 categorised as group I (non-CAD subjects), group II (CAD without myocardial infarction subjects), and group III (CAD with AMI subjects).

Results Plasma levels of sRAGE was higher in group III than in group II (p<0.01) and in group I (p<0.01). The levels of sRAGE between group II and group I were of no statistical difference (p>0.05). Further more, to evaluate whether sRAGE is the biochemical markers indicating the AMI in CAD patients, ROC curve was used, and area under the curve was 0.855(p=0.000).

Conclusion sRAGE may be new biochemical markers indicating AMI in the patients with coronary artery disease. The diagnostic sensitivity of sRAGE is 75% and specificity is 86.4%.

  • sRAGE
  • coronary artery disease, biochemical marker

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.